The stock of Jasper Therapeutics Inc. (NASDAQ: JSPR) has increased by 10.96 when compared to last closing price of 0.74.Despite this, the company has seen a loss of -10.87% in its stock price over the last five trading days. GlobeNewsWire reported 2023-09-15 that REDWOOD CITY, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced that it will participate at the Cantor Fitzgerald 2023 Global Healthcare Conference, to be held from September 26-28, 2023 in New York City.
Is It Worth Investing in Jasper Therapeutics Inc. (NASDAQ: JSPR) Right Now?
The 36-month beta value for JSPR is also noteworthy at 1.94. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average price estimated by analysts for JSPR is $6.37, which is $5.43 above than the current price. The public float for JSPR is 99.60M, and at present, short sellers hold a 1.09% of that float. The average trading volume of JSPR on September 18, 2023 was 320.42K shares.
JSPR’s Market Performance
JSPR’s stock has seen a -10.87% decrease for the week, with a -39.71% drop in the past month and a -44.22% fall in the past quarter. The volatility ratio for the week is 13.90%, and the volatility levels for the past 30 days are at 9.85% for Jasper Therapeutics Inc. The simple moving average for the past 20 days is -28.04% for JSPR’s stock, with a -43.29% simple moving average for the past 200 days.
Analysts’ Opinion of JSPR
Many brokerage firms have already submitted their reports for JSPR stocks, with CapitalOne repeating the rating for JSPR by listing it as a “Overweight.” The predicted price for JSPR in the upcoming period, according to CapitalOne is $7 based on the research report published on August 11, 2023 of the current year 2023.
JSPR Trading at -37.87% from the 50-Day Moving Average
After a stumble in the market that brought JSPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.42% of loss for the given period.
Volatility was left at 9.85%, however, over the last 30 days, the volatility rate increased by 13.90%, as shares sank -40.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.26% lower at present.
During the last 5 trading sessions, JSPR fell by -10.87%, which changed the moving average for the period of 200-days by +32.26% in comparison to the 20-day moving average, which settled at $1.1120. In addition, Jasper Therapeutics Inc. saw 69.81% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at JSPR starting from Mahal Jeetinder Singh, who sale 9,000 shares at the price of $1.66 back on Jun 13. After this action, Mahal Jeetinder Singh now owns 287,223 shares of Jasper Therapeutics Inc., valued at $14,915 using the latest closing price.
French Anna Louise, the Director of Jasper Therapeutics Inc., sale 7,000 shares at $1.48 during a trade that took place back on Apr 14, which means that French Anna Louise is holding 23,750 shares at $10,360 based on the most recent closing price.
Stock Fundamentals for JSPR
The total capital return value is set at -94.66, while invested capital returns managed to touch -68.10. Equity return is now at value -69.50, with -59.80 for asset returns.
Based on Jasper Therapeutics Inc. (JSPR), the company’s capital structure generated 10.14 points at debt to equity in total, while total debt to capital is 9.21. Total debt to assets is 7.46, with long-term debt to equity ratio resting at 7.74. Finally, the long-term debt to capital ratio is 7.03.
The liquidity ratio also appears to be rather interesting for investors as it stands at 5.91.
In summary, Jasper Therapeutics Inc. (JSPR) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.